Hypo- or hypersecretion, alteration in storage, release, catabolism, and post-translational processing of neuropeptides are associated with the etiology of many diseases affecting the central nervous system (CNS). Various peptides native to the brain and the spinal cord, as well as various synthetic peptides, peptide analogues and peptidomimetics developed as their agonists or antagonists could be useful in the treatment of these CNS maladies. However, peptides face a formidable obstacle in reaching the intended site of action due to the existence of the blood-brain barrier (BBB), a vital element in the regulation of the internal environment of the brain and the spinal cord. After reviews on the role and neuropharmaceutical potential of peptides, properties of the BBB in the context of peptide transport in the CNS and potential transport mechanisms to cross the BBB, this volume discusses the development, present state-of-the-art and future trends of various strategies to overcome this major obstacle to peptide pharmacotherapy involving the CNS. Chapters are devoted to cover invasive approaches that circumvent the BBB by direct administration into the brain or the spinal cord and by transiently opening the tight junctions of or permeabilizing the endothelial cells separating the systemic circulation from the interstitial fluid of the CNS. Subsequently, physiologically based strategies that utilize biological carriers to gain access to the CNS are discussed in detail, followed by methods encompassing prodrug and chemical delivery/targeting strategies, which aim at altering the properties of the peptide to enhance BBB transport, and drug delivery strategies based on peptide vectors. Finally, a comparative evaluation on the present status and perspectives of the techniques is presented.

lgrsnf/A:\compressed\10.1007%2F978-3-0348-8049-7.pdf

nexusstc/Peptide Transport and Delivery into the Central Nervous System/77b6ea7ddf8197afdf5ac4c39033c7e6.pdf

zlib/Medicine/Fleur L. Strand (auth.), Prof. Laszlo Prokai, Prof. Katalin Prokai-Tatrai (eds.)/Peptide Transport and Delivery into the Central Nervous System_2142801.pdf

Birkhäuser Basel : Imprint : Birkhäuser

Springer Nature Switzerland AG

Birkhäuser Boston

Birkhauser Verlag

Springer Basel

Place of publication not identified, 2003

Progress in drug research, Basel, 2003

Springer Nature, Basel, 2012

Switzerland, Switzerland

2003, Basel :

1, 2012

lg988872

{"edition":"1","isbns":["3034880499","3034894201","9783034880497","9783034894203"],"last_page":245,"publisher":"Birkhäuser Basel","series":"Progress in Drug Research 61"}

Front Matter....Pages i-viii
Neuropeptides: general characteristics and neuropharmaceutical potential in treating CNS disorders....Pages 1-37
Structural and functional aspects of the blood-brain barrier....Pages 39-78
Peptide transport across the blood-brain barrier....Pages 79-100
Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases....Pages 101-123
Altering the properties of the blood-brain barrier: disruption and permeabilization....Pages 125-154
Modifying peptide properties by prodrug design for enhanced transport into the CNS....Pages 155-188
CNS-delivery via conjugation to biological carriers: physiological-based approaches....Pages 189-219
Peptide vectors as drug carriers....Pages 221-238
Back Matter....Pages 239-245

Various peptides native to the brain and the spinal cord, as well as various synthetic peptides, peptide analogues and peptidomimetics could be useful in the treatment of diseases of the central nervous system. This book provides an overview of the role and neuropharmaceutical potential of these peptides, and discusses the state of the art and future trends in the use of peptide pharmacotherapy involving the brain.
Erscheinungsdatum: 07.11.2012

2013-08-01